Lantheus Holdings Inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
We view Lantheus Holdings' current ownership position as defined almost entirely by the pending Curium Pharma acquisition, announced August 3, 2026 at up to 114.50 dollars per share, a transaction we think reflects the board's judgment that Lantheus's standalone growth prospects, particularly given signs of PYLARIFY growth deceleration noted in fourth quarter 2025 earnings commentary, warranted accepting a substantial 38 percent premium to the stock's unaffected trading price. In our assessment, the deal's structure, combining 102.50 dollars in guaranteed cash with up to 12.00 dollars in contingent value rights tied to specific diagnostic and DEFINITY milestones through 2030, suggests negotiators on both sides sought to bridge a valuation gap between Curium's near-term offer and Lantheus shareholders' expectations for the company's longer-term pipeline value. We calculate that the roughly 6.58 billion dollar implied transaction value represents a substantial premium justified by Lantheus's 1.54 billion dollar fiscal 2025 revenue base and its position as the leading PSMA PET imaging franchise through PYLARIFY. We believe the leadership transition preceding the deal announcement, with Mary Anne Heino returning as interim CEO in November 2025 following Brian Markison's retirement, likely provided the stability needed to negotiate and finalize the merger agreement during a period of organizational change. We think shareholders should weigh the deal's expected close in the first half of 2027 against the execution risk inherent in the roughly year-long gap between announcement and closing, during which regulatory approval and shareholder votes must still occur. For Lantheus shareholders, we think the central ownership question going forward is whether the deal closes on its currently expected terms and timeline, or whether regulatory scrutiny or a competing offer introduces meaningful uncertainty before the transaction finalizes.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Vanguard Group's disclosed roughly 5.1 percent institutional stake in Lantheus Holdings represents one of the more modest largest-holder positions we have observed across recent batches, a pattern consistent with the company's shareholder base having already substantially repositioned toward the pending Curium Pharma acquisition rather than continuing conventional long-term index or active fund accumulation. We think the absence of clearly confirmed current percentages for other historically significant holders like BlackRock and RTW Investments, a specialist healthcare-focused fund that has previously held meaningful biotechnology positions, likely reflects genuine portfolio repositioning as merger arbitrage funds and event-driven strategies have taken over a larger share of trading activity following the August 2026 deal announcement. We believe this shift toward arbitrage-oriented ownership is a completely normal and expected pattern for a company under a signed, board-approved merger agreement, since long-term fundamental investors typically rotate out of positions once a deal price effectively caps near-term upside while merger arbitrage specialists step in to capture the spread between the current trading price and the deal's ultimate value. We calculate that the roughly 6.58 billion dollar market capitalization, trading close to the deal's cash-plus-contingent-value-rights terms, confirms the market broadly expects the Curium Pharma transaction to close as announced rather than face significant regulatory or shareholder opposition. We think shareholders voting on the merger agreement will likely weigh the certainty of the 102.50 dollar cash component against the more speculative value of the contingent value rights, which depend on Prostate Cancer Diagnostics, Neurology Diagnostics, and DEFINITY milestones extending out to 2030. In our assessment, this shareholder base transition from fundamental to event-driven ownership is a healthy, expected market function rather than any signal of underlying concern about the transaction. For Lantheus shareholders, we believe the practical shareholder-base question going forward is whether the deal's contingent value rights component proves attractive enough to retain shareholder support through the vote, or whether some holders would have preferred an all-cash structure.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| PYLARIFY | Brand | PSMA PET imaging agent for prostate cancer, the company's largest product at 989.1 million dollars in fiscal 2025 revenue, built on intellectual property from the 2020 Progenics Pharmaceuticals acquisition |
| DEFINITY | Brand | Ultrasound contrast agent generating 330.2 million dollars in fiscal 2025 revenue |
| NEUROLITE and TechneLite | Brand | Legacy nuclear medicine imaging agents dating to the company's origins as Bristol-Myers Squibb Medical Imaging |
| EXINI Diagnostics | Subsidiary | Sweden based artificial intelligence imaging analytics company acquired in 2020 |
| Life Molecular Imaging | Subsidiary | Alzheimer's disease radiodiagnostics company acquired in 2025 for up to 750.0 million dollars |
| Evergreen Theragnostics | Subsidiary | Radiopharmaceutical manufacturing company acquired in 2026 for 250.0 million dollars upfront and up to 1.0 billion dollars total |
Portfolio Analysis
Lantheus Holdings' brand portfolio centers on PYLARIFY, its PSMA PET imaging agent for prostate cancer that generated 989.1 million dollars in fiscal 2025 revenue and represents by far the company's most valuable asset, alongside DEFINITY, an ultrasound contrast agent contributing 330.2 million dollars in the same period. We think the PYLARIFY franchise's origins in the 2020 Progenics Pharmaceuticals acquisition illustrate how transformational a single well-timed acquisition can be for a specialty pharmaceutical company, since the imaging agent has grown to dominate the company's revenue mix within roughly six years of the underlying intellectual property acquisition. In our assessment, the 2025 Life Molecular Imaging acquisition, adding Alzheimer's disease radiodiagnostics capabilities, and the 2026 Evergreen Theragnostics acquisition, adding radiopharmaceutical manufacturing capacity, together suggest management was actively building a broader, more diversified brand portfolio even as the pending Curium Pharma transaction was likely already under negotiation. We believe the contingent value rights structure in the Curium deal, specifically tying additional payments to Prostate Cancer Diagnostics, Neurology Diagnostics, and DEFINITY milestones through 2030, effectively signals which brand franchises both companies view as having the most significant remaining growth potential beyond the current deal price. We calculate that PYLARIFY's fourth quarter 2025 growth deceleration, noted in company earnings commentary, likely factored meaningfully into Curium's willingness to structure a portion of the purchase price as contingent rather than guaranteed cash, reflecting some uncertainty about the franchise's continued growth trajectory. For Lantheus shareholders, we think the practical brand question going forward, pending the deal's close, is whether the Life Molecular Imaging and Evergreen Theragnostics acquisitions prove successful enough under Curium's ownership to trigger meaningful contingent value rights payments through 2030.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Novartis AG | N/A | N/A | Much larger pharmaceutical company with a radioligand therapy division competing in nuclear medicine, figures not separately broken out |
| Telix Pharmaceuticals | N/A | $804.0M FY2025 | Radiopharmaceutical competitor with overlapping prostate cancer imaging products |
| GE Healthcare | N/A | N/A | Diversified diagnostic imaging equipment and agent competitor, figures not separately broken out |
| Lantheus Holdings Inc. ★ | N/A | $1.54B FY2025 | Radiopharmaceutical and diagnostic imaging company, currently under a pending acquisition agreement with Curium Pharma |
Competitive Analysis
Lantheus Holdings competes within a specialized radiopharmaceutical and diagnostic imaging landscape that includes Telix Pharmaceuticals, whose fiscal 2025 revenue of roughly 804.0 million dollars grew substantially from roughly 517.0 million dollars the prior year, alongside much larger diversified competitors including Novartis's radioligand therapy division and GE Healthcare's broader diagnostic imaging agent business, neither of which breaks out directly comparable segment revenue. We think Telix Pharmaceuticals represents the more directly comparable pure-play competitor given its similar focus on prostate cancer imaging and radiopharmaceutical products, making its strong growth trajectory a useful benchmark against PYLARIFY's own more recent deceleration. We believe Lantheus's decision to accept Curium Pharma's acquisition offer, rather than continuing to compete independently against Telix's accelerating growth and the radioligand therapy investments of much larger pharmaceutical companies, reflects a judgment that scale and combined manufacturing capabilities under Curium's ownership offer a more competitive path forward than continued standalone operation. We calculate that Curium Pharma itself, as a specialist radiopharmaceutical manufacturer, likely views the Lantheus acquisition as a way to meaningfully strengthen its own competitive position against both Telix Pharmaceuticals and the radioligand therapy divisions of diversified pharmaceutical giants like Novartis. In our assessment, the combined Curium-Lantheus entity, once the deal closes, should have meaningfully greater manufacturing scale and a broader diagnostic and therapeutic radiopharmaceutical portfolio than either company possessed independently, a genuinely different competitive position than Lantheus occupies today as a standalone public company. We think PYLARIFY's fourth quarter 2025 growth deceleration specifically underscores why competitive pressure from Telix and other emerging radiopharmaceutical players likely factored into Lantheus's board decision to accept Curium's offer rather than continue competing independently. For Lantheus shareholders, we believe the central competitive question, pending the deal's close, is whether the combined Curium-Lantheus entity emerges as a stronger competitor against Telix Pharmaceuticals and the radioligand therapy ambitions of larger pharmaceutical companies than Lantheus could have achieved alone.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Progenics Pharmaceuticals | Undisclosed | 2020 | Acquisition bringing PSMA PET imaging intellectual property that underlies the PYLARIFY franchise |
| EXINI Diagnostics | Undisclosed | 2020 | Sweden based artificial intelligence imaging analytics acquisition |
| Life Molecular Imaging | $750.0M | 2025 | Alzheimer's disease radiodiagnostics acquisition, up to 750.0 million dollars total consideration |
| Evergreen Theragnostics | $1.0B | 2026 | Radiopharmaceutical manufacturing acquisition, 250.0 million dollars upfront with up to 1.0 billion dollars total consideration |
Acquisitions Analysis
Lantheus Holdings has pursued an increasingly active acquisition strategy in recent years, culminating in the 2025 Life Molecular Imaging deal worth up to 750.0 million dollars and the 2026 Evergreen Theragnostics acquisition worth up to 1.0 billion dollars total consideration, both arriving in the years immediately preceding the company's own pending acquisition by Curium Pharma. We think this acceleration in acquisition activity, building on the foundational 2020 Progenics Pharmaceuticals and EXINI Diagnostics deals that created the PYLARIFY franchise, suggests management was actively expanding the company's radiopharmaceutical manufacturing and diagnostic capabilities right up until the point Curium's offer emerged. We believe the Evergreen Theragnostics acquisition specifically, adding radiopharmaceutical manufacturing capacity, likely made Lantheus a more attractive and complete acquisition target for Curium Pharma, itself a specialist radiopharmaceutical manufacturer, by reducing the integration complexity Curium would otherwise face post-acquisition. We calculate that the combined up to 1.75 billion dollars in potential consideration across the Life Molecular Imaging and Evergreen Theragnostics deals represents substantial capital deployment in the two years immediately preceding Lantheus's own sale, a pattern that could reflect either confident standalone growth investment or deliberate positioning to maximize the company's eventual sale value. We think the timing sequence, with both acquisitions closing before the August 2026 Curium Pharma announcement, suggests Curium's due diligence process likely valued these recently acquired capabilities as part of the overall 114.50 dollar per share offer. For Lantheus shareholders, we believe the practical acquisitions question going forward is largely moot pending the Curium deal's close, since these recent acquisitions will become part of Curium's broader radiopharmaceutical portfolio rather than continuing under independent Lantheus ownership.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Lantheus Holdings' merger history now centers on the pending Curium Pharma acquisition, announced August 3, 2026 and valued at up to 114.50 dollars per share combining 102.50 dollars in cash with up to 12.00 dollars in contingent value rights, representing by far the most significant transaction in the company's history since its 2015 initial public offering. We think the deal's roughly 6.58 billion dollar implied value, alongside the 38 percent premium to the stock's unaffected trading price, reflects Curium Pharma's assessment that Lantheus's PYLARIFY franchise and recently expanded manufacturing capabilities from the Life Molecular Imaging and Evergreen Theragnostics acquisitions justify a substantial acquisition premium despite some recent growth deceleration signals. In our assessment, the transaction's expected closing timeline in the first half of 2027, roughly a year after the August 2026 announcement, reflects the typical regulatory review period for a healthcare sector acquisition of this scale, during which the deal remains subject to shareholder approval and antitrust clearance. We believe the leadership transition preceding the deal, with Mary Anne Heino returning as interim CEO in November 2025 after Brian Markison's retirement, likely provided important continuity during the merger negotiation process, though it also means the company will complete this transformational transaction without a permanent, deal-independent CEO in place. We calculate that the contingent value rights structure, tying additional payments to specific diagnostic and DEFINITY milestones through 2030, represents a genuinely creative deal mechanism that allows both parties to bridge disagreement about the company's longer-term pipeline value rather than settling on a single fixed price. For Lantheus shareholders, we think the merger history's key lesson is that even a company built through aggressive acquisition, spanning Progenics Pharmaceuticals, EXINI Diagnostics, Life Molecular Imaging, and Evergreen Theragnostics, can itself become an acquisition target once a larger strategic buyer identifies sufficient value in the combined capabilities those deals created.
Ownership History
Ownership History Analysis
Lantheus Holdings' ownership history traces back to its 1956 origins as Bristol-Myers Squibb Medical Imaging, followed by eventual corporate separation and a 2015 initial public offering that established the company as an independent, publicly traded entity on Nasdaq. We think the roughly eleven years since that public offering have been marked by an increasingly acquisitive growth strategy, beginning with the transformational 2020 Progenics Pharmaceuticals and EXINI Diagnostics deals and accelerating through the 2025 Life Molecular Imaging and 2026 Evergreen Theragnostics acquisitions, culminating now in the company's own pending sale to Curium Pharma. In our assessment, this trajectory, from a divested pharmaceutical imaging division to an independent acquirer building its own radiopharmaceutical portfolio to now itself becoming an acquisition target, represents a genuinely complete corporate lifecycle within roughly seven decades. We believe the pending Curium Pharma transaction, if it closes as expected in the first half of 2027, will mark the definitive end of Lantheus's independent public company chapter, transferring PYLARIFY, DEFINITY, and the company's recently expanded manufacturing capabilities to private ownership under a specialist radiopharmaceutical manufacturer. We calculate that shareholders who held Lantheus stock through this entire public company period will have captured value both from the underlying business's growth and from the substantial acquisition premium Curium Pharma is paying to complete the transaction. For anyone tracking Lantheus Holdings' ownership trajectory, we think the period between now and the deal's expected close in the first half of 2027 is worth watching closely, since shareholder votes, regulatory review, and the ultimate realization of the contingent value rights will determine how this ownership chapter concludes.
Ownership Explained
Lantheus Holdings Inc. is a widely held public company with no founder or family controlling stake, trading on the Nasdaq Global Select Market under ticker LNTH since its 2015 initial public offering, and currently the subject of a definitive merger agreement announced August 3, 2026 under which Curium Pharma will acquire the company for up to 114.50 dollars per share. Vanguard Group holds a disclosed institutional stake of roughly 5.1 percent, though the pending transaction has meaningfully shifted investor attention toward the deal's approval timeline rather than ongoing institutional accumulation. The company reported fiscal 2025 total revenue of 1.54 billion dollars, driven substantially by PYLARIFY, its PSMA PET prostate cancer imaging agent, which generated 989.1 million dollars in revenue. Interim Chief Executive Officer Mary Anne Heino, who returned to the role in November 2025 following Brian Markison's retirement, is overseeing the pending Curium Pharma transaction alongside the company's most recent acquisitions of Life Molecular Imaging and Evergreen Theragnostics.
For hospitals and imaging centers using PYLARIFY and DEFINITY, Lantheus Holdings' pending acquisition by Curium Pharma means the radiopharmaceutical products they depend on will likely continue under new private ownership once the deal closes, expected in the first half of 2027, though supply and pricing decisions may eventually reflect Curium's broader strategic priorities rather than Lantheus's current standalone approach. For shareholders, the pending transaction means the company's stock price has already converged toward the deal's cash and contingent value rights terms, with the ultimate payout depending on whether the Prostate Cancer Diagnostics, Neurology Diagnostics, and DEFINITY milestones underlying the contingent value rights are achieved through 2030. Until the deal closes, Lantheus remains a fully independent, publicly traded company subject to its own board's fiduciary obligations, meaning shareholders retain the ability to vote on the transaction and the deal remains subject to regulatory approval that could still alter its terms or timeline.